

# Effect of Chromium Supplementation on Glucose Metabolism and Lipids

A systematic review of randomized controlled trials

ETHAN M. BALK, MD, MPH<sup>1</sup>  
ATHINA TATSIONI, MD<sup>1</sup>  
ALICE H. LICHTENSTEIN, DSC<sup>2</sup>

JOSEPH LAU, MD<sup>1</sup>  
ANASTASSIOS G. PITTAS, MD, MSC<sup>3</sup>

**OBJECTIVE** — A systematic review of the effect of chromium supplementation on glucose metabolism and lipid levels.

**RESEARCH DESIGN AND METHODS** — A literature search was conducted in MEDLINE and the Commonwealth Agricultural Bureau. Eligible studies were English language randomized controlled trials of chromium supplement intake  $\geq 3$  weeks, with  $\geq 10$  participants receiving chromium. All trials with glucose metabolism outcomes and trials of individuals with diabetes or glucose intolerance for lipid outcomes were included. Meta-analyses were performed as appropriate.

**RESULTS** — Forty-one studies met criteria, almost half of which were of poor quality. Among participants with type 2 diabetes, chromium supplementation improved glycosylated hemoglobin levels by  $-0.6\%$  (95% CI  $-0.9$  to  $-0.2$ ) and fasting glucose by  $-1.0$  mmol/l ( $-1.4$  to  $-0.5$ ) but not lipids. There was no benefit in individuals without diabetes. There were some indications of dose effect and differences among chromium formulations. Larger effects were more commonly observed in poor-quality studies. The evidence was limited by poor study quality, heterogeneity in methodology and results, and a lack of consensus on assessment of chromium status.

**CONCLUSIONS** — No significant effect of chromium on lipid or glucose metabolism was found in people without diabetes. Chromium supplementation significantly improved glycemia among patients with diabetes. However, future studies that address the limitations in the current evidence are needed before definitive claims can be made about the effect of chromium supplementation.

*Diabetes Care* 30:2154–2163, 2007

Chromium is an essential mineral that is thought to be necessary for normal glucose and lipid homeostasis (1–3). Trivalent chromium in a complex known as glucose tolerance factor is considered the biologically active form. It was originally discovered in brewer's yeast (4). Chromium chloride, chromium nicotinate, and chromium picolinate are commonly used formulations of trivalent

chromium. Chromium picolinate is a formulation designed to improve absorption (5). Severe chromium deficiency is known to cause reversible insulin resistance and diabetes (6–8). However, the effect of chromium supplementation in individuals who are not severely chromium deficient is unclear. Manufacturers aggressively promote the benefits of chromium in the prevention and treatment of

insulin resistance and its associated conditions (type 2 diabetes, dyslipidemia, and cardiovascular disease), and the public has embraced its use. Chromium supplement sales represent  $\sim 6\%$  of the U.S. mineral supplement market (9).

To clarify the role of chromium supplementation in the prevention and management of abnormal glucose and lipid homeostasis, we performed a systematic review of randomized controlled trials on the effect of chromium supplement intake on glucose metabolism and lipid profile.

## RESEARCH DESIGN AND METHODS

### Literature search and eligibility criteria

We conducted a systematic review of the English-language literature on the effects of chromium supplementation on glucose metabolism and lipids in nonpregnant adults in MEDLINE and Commonwealth Agricultural Bureau databases through 8 August 2006 (10). Search terms included chromium, diabetes mellitus, glycemia, glycosylated hemoglobin, metabolic syndrome, insulin resistance, and related terms. Additional publications were identified by domain experts and from review articles and citations included in a petition to the U.S. Food and Drug Administration regarding health claims for chromium picolinate (11).

We evaluated randomized controlled trials of chromium supplements, regardless of formulation. For studies with outcomes related to glucose metabolism, we included studies of individuals with type 1 or type 2 diabetes, glucose intolerance, or normal glucose tolerance. "Glucose intolerance" was defined based on the World Health Organization or American Diabetes Association criteria as either impaired fasting glucose (fasting plasma glucose 5.6–7.0 mmol/l) or impaired glucose tolerance (2-h postload glucose concentration 7.8–11.1 mmol/l); "normal glucose tolerance" was defined as either fasting plasma glucose  $< 5.6$  mmol/l or a 2-h postload glucose concentration  $< 7.8$  mmol/l (12,13). For studies with lipid

From the <sup>1</sup>Institute for Clinical Research and Health Policy Studies, Tufts-New England Medical Center, Boston, Massachusetts; the <sup>2</sup>Clinical Nutrition Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, Massachusetts; and the <sup>3</sup>Division of Endocrinology, Diabetes and Metabolism, Tufts-New England Medical Center, Boston, Massachusetts.

Address correspondence and reprint requests to Ethan Balk, Institute for Clinical Research and Health Policy Studies, Tufts-New England Medical Center, 750 Washington St., NEMC #63, Boston, MA 02111. E-mail: ebalk@tufts-nemc.org.

Received for publication 15 May 2006 and accepted in revised form 14 May 2007.

Published ahead of print at <http://care.diabetesjournals.org> on 22 May 2007. DOI: 10.2337/dc06-0996. Additional information for this article can be found in an online appendix at <http://dx.doi.org/10.2337/dc06-0996>.

**Abbreviations:** AUC-Glu, glucose area under the curve.

A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

© 2007 by the American Diabetes Association.

outcomes, we included only studies whose participants had either diabetes or glucose intolerance because chromium's effect on insulin action is the putative mechanism by which chromium may affect lipids (14).

We excluded studies of <3 weeks' duration with <10 participants receiving chromium (but allowed smaller subsets of participants within larger studies), as well as letters, abstracts, and conference proceedings. Two reviewers independently screened abstracts and articles and subsequently extracted data. Discrepancies were resolved by consensus among all co-authors.

Outcomes of interest included glycosylated hemoglobin, fasting glucose, post-load glycemia, insulin sensitivity, and lipoprotein (LDL, HDL, and triglyceride) levels.

### Quantitative analysis

We evaluated the net difference between the within-treatment (chromium supplementation) effect and the within-placebo effect. For glycosylated hemoglobin, fasting glucose, and the lipoprotein outcomes, we performed random effects model meta-analyses (15). We analyzed HbA<sub>1c</sub> and total glycosylated hemoglobin as equivalent to A1C, as they reflect glycemia similarly (16). When necessary, we estimated the SE of the net change from reported variance data, including *P* values. To compare differences across different subanalyses, *t* tests were performed. For other outcomes, we did not perform meta-analysis due to lack of uniformity in measuring these outcomes.

### Study quality assessment

Methodological quality refers to the design, conduct, and reporting of the clinical study. The quality of each study was assessed by at least two authors using a 3-level classification (17); discrepancies were resolved by consensus of the co-authors. Good-quality studies likely had the least bias; they provided clear descriptions of the populations, settings, interventions, and comparison groups; used appropriate measurement of outcomes; used appropriate analytic methods, including blinding and appropriate controls; had no obvious reporting errors; had <20% drop out and clear reporting of drop outs; reported relevant outcomes quantitatively; and had no obvious bias. Fair-quality studies had some deficiencies but none likely to cause major bias or may be missing information limiting assess-

ment. Poor-quality studies are susceptible to substantial bias, had serious errors in design or analysis, may have had large amounts of missing information or discrepancies in reporting, or had outcomes that were so poorly reported that estimates could not be assessed by the reader.

**RESULTS**— The literature search yielded 793 citations. We retrieved 96 articles, of which 41 met eligibility criteria (online appendix Fig. 1 [available at <http://dx.doi.org/10.2337/dc06-0996>]).

### Characteristics of all evaluated studies

The studies included 1,198 participants who received four different chromium formulations (all doses throughout are elemental chromium): brewer's yeast (1.28–400  $\mu\text{g}/\text{day}$ , 10 studies) (18–27), chromium chloride (50–600  $\mu\text{g}/\text{day}$ , 15 studies) (21,22,24,27–38), chromium nicotinate (200–800  $\mu\text{g}/\text{day}$ , 5 studies) (39–43), and chromium picolinate (60–1,000  $\mu\text{g}/\text{day}$ , 15 studies) (39,44–57). One study did not describe the chromium formulation (400  $\mu\text{g}/\text{day}$ ) (58). Almost all study participants with diabetes had type 2, although in three studies this was unclear (22,29,31). No study included only patients with type 1 diabetes. Study duration ranged from 3 weeks to 8 months. Nine studies were funded by the food or supplement industry, 18 were funded by nonindustry sources, and 14 did not report funding source. Five studies were graded good quality, 18 fair quality, and 18 poor quality. Several studies attempted to measure participants' baseline chromium status, but a large variety of methods were used, and no study adequately assessed the possible impact of baseline chromium status on outcomes.

### Glucose metabolism

**Glycosylated hemoglobin.** Fourteen studies with 18 intervention arms evaluated the effect of chromium supplementation on glycosylated hemoglobin in 431 participants (receiving chromium) with either type 2 diabetes or glucose intolerance (18–20,28,39,44–51,58) (Fig. 1 and online appendix Table 1). The overall estimate of chromium supplementation in people with diabetes was statistically significant ( $-0.6\%$  [95% CI  $-0.9$  to  $-0.2$ ]). However, 11 of 14 interventions found a null or statistically nonsignificant effect. Anderson et al. (44) found a dose effect where high doses of chromium picolinate (1,000  $\mu\text{g}/\text{day}$ ) were more effec-

tive than low doses (200  $\mu\text{g}/\text{day}$ ,  $P < 0.05$ ), but Kleefstra et al. (45) found no difference between 1,000 and 500  $\mu\text{g}/\text{day}$ . No study of participants with glucose intolerance found a statistically significant effect of chromium supplementation on glycosylated hemoglobin (20,39,51).

### Fasting glucose

The effect of chromium supplementation in a wide range of doses on fasting glucose was evaluated in 38 studies with 1,140 participants who had either type 2 diabetes, glucose intolerance, or normal glucose tolerance (Fig. 2 and online appendix Table 1).

### Participants with type 2 diabetes

Seventeen studies with 23 chromium arms evaluated participants with diabetes (18,19,21–23,28–31,44,46–50,52,58) (Fig. 2A). The majority found no effect of chromium supplementation on fasting glucose. Seven of the 17 studies reported a statistically significant reduction in fasting glucose (18,21,23,44,46,48,58), and 2 additional studies stated there were large reductions in fasting glucose but did not report statistical significance (29,52).

The overall estimate for the effect of supplementation with brewer's yeast on fasting glucose was statistically significant ( $-1.1$  mmol/l [95% CI  $-1.6$  to  $-0.6$ ]) but without a clear dose effect. Consistent with this, the study by Rabinowitz et al. (22) found no significant difference in fasting glucose among participants taking two relatively low doses of brewer's yeast (6 and 18  $\mu\text{g}$ ). Chromium picolinate had a significant effect on fasting glucose ( $-0.8$  mmol/l [ $-1.2$  to  $-0.3$ ]). Across studies, doses of 400 or 1,000  $\mu\text{g}/\text{day}$  appear to have had greater effects than lower doses. This was borne out by one study that directly compared doses (44).

Among studies of chromium chloride, there was no significant effect on fasting glucose ( $-0.3$  mmol/l [95% CI  $-0.9$  to  $+0.2$ ]). The single study with a large effect on fasting glucose used a relatively high dose (600  $\mu\text{g}/\text{day}$ ), although this study was deficient in numerous ways, including lack of statistical analysis, inadequate randomization, and a range of treatment durations (29).


The two studies that compared brewer's yeast to chromium chloride found no significant difference between the two supplements (21,22).

**A**

Study	Year	Cr Form	Elemental Cr Dose (mcg/day)	Duration (weeks)	N	Baseline (%)
Racek	2006 (18)	BrY	400	12	19	7.2
Grant	1982 (19)	BrY	1.28	7	37	8.1
56						
Uusitupa	1983 (28)	CrCl	200	6	10	10.1
Anderson	1997 (44)	CrPic	1000	17	52	9.4
Kleefstra	2006 (45)	CrPic	1000	26	15	9.7
Martin	2006 (46)	CrPic	1000	24	14	9.7
Vrtovek	2005 (47)	CrPic	1000 (or 120) †	13	30 §	7
Vrtovek	2005 (47)	CrPic	1000 (or 120) ‡	13	30	6.9
Kleefstra	2006 (45)	CrPic	500	26	14	9.4
Ghosh	2002 (48)	CrPic	400	12	43	7.2
Anderson	1997 (44)	CrPic	200	17	53	9.4
Evans	1989 (49)	CrPic	200	5	6	10.4
Lee	1994 (50)	CrPic	200 (or 24) †	9	28	nd
285						
Pei	2006 (58)	CrMilk	400	16	30	9.3
381						
151						
54						
176						
135						
52						
194						

**B**

Uusitupa	1992 (20)	BrY	160	26	13	5.4
Grant	1997 (39)	CrNic	400	9	11	nd
Cefalu	1999 (51)	CrPic	1000	33	15	nd
Grant	1997 (39)	CrPic	400	9	11	nd



**Figure 1**—Meta-analysis of randomized controlled trials of the effect of chromium supplementation on A1C (or other measures of glycosylated hemoglobin) in participants with type 2 diabetes (A) and participants with glucose intolerance (B). The point estimates of the net changes (change in chromium arm minus change in control arm) and the corresponding 95% CI for individual studies are indicated by circles and bars. The random effects model summary estimates are indicated by squares and bars. Black squares indicate summary estimate of all studies; white squares indicate subanalyses, as indicated. Studies are arranged by chromium formulation (Cr Form), then dose, and then number of participants consuming Cr (N). Total numbers refer only to studies included in the meta-analyses. “Glucose intolerance” is defined based on the World Health Organization or American Diabetes Association criteria as either impaired fasting glucose (fasting plasma glucose 5.6–7.0 mmol/l) or impaired glucose tolerance (2-h postload glucose 7.8–11.1 mmol/l) (12,13). Quality: A = good; B = fair; C = poor. \*Hb A<sub>1c</sub>, not A1C; †total glycosylated hemoglobin; ‡unclear if dose refers to elemental chromium or total chromium picolinate; §cross-over study (received placebo first, followed by chromium picolinate); ||cross-over study (received chromium picolinate first, followed by placebo); ¶no numerical data results reported. BrY, brewer’s yeast; Cr, chromium; CrCl, chromium chloride; CrMilk, milk powder with chromium (no data on chemical formulation); CrNic, chromium nicotinate; CrPic, chromium picolinate; DM, diabetes; ND, no data.

**Participants with glucose intolerance**

Eight studies with 11 arms included participants with glucose intolerance (20,32–34,39,40,53,54) (Fig. 2B). None reported a significant effect on fasting glucose. Overall estimates for both chromium chloride and chromium picolinate each found nil effects.

**Participants with normal glucose tolerance**

Nineteen studies with 23 arms included participants with normal glucose tolerance (Fig. 2C), 22 of which found no sta-

tistically significant effect of chromium supplementation on fasting glucose (23–27,30–38,41–43,55,56). The studies that evaluated chromium chloride, nicotinate, and picolinate were statistically homogeneous in finding no significant net effect of chromium supplementation. In meta-analysis of brewer’s yeast, the studies were statistically heterogeneous and the summary estimate nonsignificant. Across studies, doses of brewer’s yeast with >10 µg/day chromium had larger net decreases in fasting glucose than lower doses, which is consistent with the one study that directly compared doses (27).

**Nonfasting (post-glucose load) measures of glycemia**

Various glycemia measurements were reported after a variety of oral glucose tolerance tests in 25 studies in 822 participants receiving chromium (online appendix Tables 1–3). There was little consistency in glucose load, timing of measurements, or outcome metrics used. Thus, meta-analysis was not performed.

**Participants with type 2 diabetes**

Among the seven studies of participants with diabetes (19,21–23,28,31,44), only one found a statistically significant im-

provement in 2-h postload glycemia with either 200 or 1,000  $\mu\text{g/day}$  chromium picolinate; the net decrease was greater with the higher dose supplement ( $-1.9$  vs.  $-1.4$  mmol/l, respectively) (44). The remaining studies of brewer's yeast or chromium chloride reported net changes in 2-h postload glucose of  $-1.2$  to  $+0.3$  mmol/l or a net change in the glucose area under the curve (AUC-Glu) of  $-24$  to  $+24\%$ , none of which was statistically significant.

### Participants with glucose intolerance

Among the nine studies of participants with glucose intolerance (20,32–34,39,46,53,54,58), only Anderson et al. (32,33), in two separate studies of 200  $\mu\text{g/day}$  chromium chloride, reported statistically significant improvements in postload glucose levels with chromium supplementation: in one, an 8% reduction in 4-h AUC-Glu (but not in 3-h AUC-Glu) and in the other a 1.1 mmol/l reduction in 90-min postload glucose. Other studies of all four chromium formulations reported nonsignificant changes in AUC-Glu of  $-21$  to  $+3\%$  and in various timed postload glucose levels of  $-1.5$  to  $+0.4$  mmol/l.

### Participants with normal glucose tolerance

No consistent effect of chromium on postload glycemia was reported among the 14 studies of participants with normal glucose tolerance (23,25–27,31–34,36,37,41,43,55,56). In contrast to their other findings, Anderson et al. (32) found that in participants with normal glucose tolerance, the 90-min postload glucose level significantly increased in participants on 200  $\mu\text{g/day}$  chromium. Across other studies of all four chromium formulations, no effect was evident, with AUC-Glu changing between  $-17$  and  $+2\%$  and various timed postload glucose levels changing between  $-2.3$  and  $+1.8$  mmol/l but without statistical significance.

### Insulin sensitivity

Nine studies, with 138 participants receiving chromium, reported data on insulin sensitivity in participants with either normal glucose tolerance or glucose intolerance (24,27,37,46,51,54,56–58) (online appendix Table 4). Each study used a different surrogate of insulin sensitivity based on fasting or postload values of glucose and insulin

(insulin-to-glucose ratio, homeostasis model assessment of insulin resistance, and “relative insulin”) or after an intravenous glucose tolerance test ( $S_i$ ). Only one study used the euglycemic-hyperinsulinemic clamp (46). All but two studies reported no significant change in insulin sensitivity. Cefalu et al. (51), in a study of 1,000  $\mu\text{g/day}$  chromium picolinate in obese participants with a first-degree relative with diabetes, found a 70% net improvement in  $S_i$  estimated by the minimal model after an intravenous glucose tolerance test. However, there was a 25% (nonstatistically significant) difference in baseline  $S_i$  between the chromium and the control groups. In a later study by an overlapping group of researchers, Martin et al. (46) found that patients with moderately controlled type 2 diabetes (fasting glucose between 6.9 and 9.4  $\mu\text{mol/l}$  at baseline) taking 1,000  $\mu\text{g/day}$  chromium picolinate had a statistically significant increase in glucose disposal during a euglycemic-hyperinsulinemic clamp, whereas those on placebo had a nonsignificant decrease. However, no analysis was reported that directly compared chromium with placebo, and our estimate of the net change, using reported data, was nonsignificant ( $+13$  mg/min per fat-free mass [95% CI  $-29$  to  $+55$ ]).

### Lipid profiles

Eighteen studies, with 655 participants receiving chromium, reported lipid data in participants with either type 2 diabetes or glucose intolerance (18–23,28,29,44–46,48–50,52–54,56,58) (Fig. 3 and online appendix Table 5).

### LDL cholesterol

None of the nine studies with LDL cholesterol data reported a statistically significant effect, regardless of chromium formulation or dose (18,20,28,45,48–50,53,58). The overall estimate of effect for chromium supplementation in all participants was nonsignificant ( $-0.31$  mmol/l [95% CI  $-0.73$  to  $+0.11$ ]).

### HDL cholesterol

Twelve studies evaluated HDL cholesterol (18–21,28,29,44,45,48,50,53,58). Two studies of lower-dose brewer's yeast (1 and 23  $\mu\text{g}$ ) in participants with type 2 diabetes found similar large, statistically significant net increases in HDL cholesterol (19,21), but chromium enriched, high-dose brewer's yeast (400  $\mu\text{g}$ ) did not

affect HDL cholesterol in a third study (18). The single study of brewer's yeast in participants with glucose intolerance found no net effect (20). The three studies of chromium chloride supplementation in participants with diabetes were heterogeneous, finding a range of effects (0.0–0.6 mmol/l) (21,28,29). All six studies of chromium picolinate in participants with either diabetes or glucose intolerance found no effect on HDL cholesterol (44,45,48,50,53,58).

Individual studies found no difference in effect between brewer's yeast and chromium chloride or between different chromium picolinate doses (21,44,45).

### Triglycerides

Seventeen studies reported on triglyceride effect (18–23,28,44–46,48–50,52–54,56,58), 15 of which found no statistically significant effect. Overall estimates for the tested chromium supplements (brewer's yeast, chromium chloride, and chromium picolinate) were each nonsignificant in participants with either type 2 diabetes or glucose intolerance (44,49,52), as was meta-analysis across the studies.

### Study heterogeneity

We analyzed a number of factors to explain the statistically heterogeneity of most of the meta-analyses.

### Chromium formulation


Some heterogeneity could be explained by differences in effect between the various chromium formulations. Among participants with type 2 diabetes, the effects of brewer's yeast, chromium chloride, and chromium picolinate on fasting glucose were each significantly different from each other ( $P < 0.02$ ), such that studies of brewer's yeast had the greatest net effect ( $-1.1$  mmol/l), followed by chromium picolinate ( $-0.8$  mmol/l) and chromium chloride ( $-0.3$  mmol/l). Similarly, among studies of participants with normal glucose tolerance, brewer's yeast was significantly more likely to reduce fasting glucose than chromium chloride ( $-0.2$  vs.  $+0.1$  mmol/l,  $P = 0.01$ ) and to raise HDL cholesterol than chromium picolinate ( $+0.21$  vs.  $-0.02$ ,  $P = 0.002$ ). In the few studies that directly compared different chromium formulations, none found differences (21,22,24,27,39).

### Dose effect


The association between chromium dose and effect was difficult to interpret, in part




**A**



**B**





**Figure 2**—Meta-analyses of randomized controlled trials of the effect of chromium supplementation on fasting glucose in participants with type 2 diabetes (A), participants with glucose intolerance (B), and participants with normal glucose tolerance (C). See Fig. 1. “Normal glucose tolerance” is defined as either fasting plasma glucose <5.6 mmol/l or 2-h postload glucose concentration <7.8 mmol/l (12,13). \*Range of times when final FBS was drawn; †only point estimate reported (not included in meta-analyses); ‡participants with non-insulin-dependent type 2 diabetes; §participants with insulin-dependent type 2 diabetes; ||unclear if dose refers to elemental chromium or total chromium picolinate; ¶cross-over study (received placebo first, followed by chromium picolinate); #cross-over study (received chromium picolinate first, followed by placebo); \*\*glucose level 90 min after glucose tolerance test <100 mg/dl but greater than fasting glucose level; ††glucose level 90 min after glucose tolerance test >100 mg/dl; ‡‡study participants taking a “medication with hyperglycemic potential;” §§study participants not taking a “medication with hyperglycemic potential;” ||||one participant had type 2 diabetes, and the remaining participants had normal glucose tolerance.

because the exact dose was unclear in a number of chromium picolinate studies and the number of studies using different doses were small for several outcomes. In patients with diabetes, the effect of chromium picolinate on glycosylated hemoglobin and fasting glucose may have been greater in those studies that definitely used chromium doses of at least 200 µg/day or of 1,000 µg/day, respectively (Figs. 1A and 2A). However, both of these possible effects were largely driven by the single study that directly compared 200 µg and 1,000 µg chromium picolinate, which found greater effects with the higher dose (44). In participants with normal glucose tolerance, doses of brewer’s yeast of at least 10 µg/day chromium may also have lowered fasting glucose more than lower

doses, a finding confirmed by one study (27) (Fig. 2C). Most studies that compared doses did not find differences for several outcomes (21,22,27,41,44,45).

**Study quality and funding source**


For glycosylated hemoglobin in participants with type 2 diabetes (Fig. 1A) and for fasting glucose in participants with diabetes or normal glucose tolerance (Fig. 2C), poor-quality studies (B or C) had significantly greater favorable net effects than high-quality studies (A) ( $P < 0.03$ ).

There was a trend among studies of fasting glucose in participants with diabetes (Fig. 2A) in that studies funded by industry had greater net improvements than other studies ( $P = 0.06$ ). For other outcomes and subpopulations, there was

no evidence of bias based on study quality or funding source.

**CONCLUSIONS**

— Three-quarters of the 36 studies reviewed found no statistically significant effect on measured outcomes. However, most of the studies were inadequately powered; thus, lack of a statistically significant result may not indicate a lack of effect. Almost one-half of the studies were of poor quality, and there was substantial heterogeneity across studies in chromium formulations and doses used, in settings (and thus possibly underlying states of chromium nutrature), and in results. Though meta-analysis resulted in statistically significant improvements in glycemic control among patients



**Figure 3**—Meta-analyses of randomized controlled trials of the effect of chromium supplementation on lipids, including LDL, HDL, and triglycerides, in participants with type 2 diabetes (A) and participants with glucose intolerance (B). See Fig. 1. Gray squares indicate summary estimates of combination of all studies, regardless of glucose status. \*Range of times when final HDL level was drawn; †variance data not reported and not included in meta-analysis; ‡no results data reported; §unclear if dose refers to elemental chromium or total chromium picolinate.

with type 2 diabetes, given the poor quality and heterogeneity of much of the data, future studies that address the limitations in the current evidence are needed before definitive claims can be made about the effect of chromium supplementation.

In people with type 2 diabetes, our results show that, on average, chromium picolinate supplementation lowered A1C by 0.6% and that brewer’s yeast and chromium picolinate lowered fasting glucose by 1.1 and 0.8 mmol/l, respectively. Overall, chromium supplementation did not affect lipid levels in people with type 2 diabetes or glucose intolerance, although brewer’s yeast supplementation did statistically significantly raise HDL cholesterol by 0.21 mmol/l, which was a significantly greater effect than chromium picolinate.

Dose effects would provide confirmation of a beneficial effect of chromium supplementation. However, the dose effects were found across studies primarily for chromium picolinate and were driven largely by a single study (44). Likewise, a single study drove a possible difference between higher and lower dose brewer’s

yeast on fasting glucose in participants with normal glucose tolerance (27). Four other studies found no differences among different doses (21,22,41,45). Assessment of dose effects was hampered by the small number and size of studies comparing different doses.

In people with either normal glucose tolerance or glucose intolerance, chromium supplementation did not appear to have an effect on measures of glycemia, nor did chromium improve lipid profiles among people with glucose intolerance.

Chromium is thought to be a cofactor necessary for optimal insulin action (1–3). Therefore, chromium supplementation may exert its potential benefits by improvement in insulin sensitivity. Nearly all studies that examined the effect of chromium on insulin sensitivity found no significant effect. The exception, Cefalu et al. (51), found a statistically significant improvement in insulin sensitivity in relatives of patients with diabetes in a small study with considerable differences in baseline insulin sensitivity. Although the authors properly controlled for pre-

randomization levels in their analyses, the large difference raises the concern that either the groups were not adequately randomized or that the distribution of insulin sensitivity values may have been skewed for some unknown reason. Even with adjustment, interpretation of the results is difficult, and future studies would need to confirm the finding. On the basis of this study, the U.S. Food and Drug Administration recently gave chromium picolinate the food-related health claim that it “may reduce the risk of insulin resistance, and therefore possibly may reduce the risk of type 2 diabetes . . . however, the existence of such a relationship between chromium picolinate and either insulin resistance or type 2 diabetes is highly uncertain” (59). Assessing the effect of chromium on insulin sensitivity is further hampered by the lack of studies with robust measures of insulin sensitivity, such as the euglycemic-hyperinsulinemic clamp.

Differences in effect between the four different chromium formulations were difficult to assess. Subgroup meta-analyses did show some statistically sig-

nificant and some qualitative differences in effects between formulations, such that brewer's yeast and chromium picolinate significantly lowered fasting glucose in people with type 2 diabetes, while the effect of chromium chloride was nonsignificant; brewer's yeast raised HDL cholesterol levels more than chromium chloride and chromium picolinate. However, these and other indirect comparisons across studies are hypothesis-generating only. With few studies directly comparing different factors such as dose and formulation, it is difficult to be conclusive about differences in effect. Only five studies directly compared different chromium formulations, and none found any differences among them. However, it is notable that brewer's yeast had similar effects as other chromium formulations despite substantially lower doses of chromium, possibly suggesting that another component in brewer's yeast has an effect on insulin sensitivity. We were unable to evaluate differences in formulation and dose together; however, the differences in effect of low-chromium dose brewer's yeast compared with high-dose chromium in other formulations suggest that the effect of chromium doses may not be comparable in different formulations.

Overall, the quality of the studies on chromium supplementation was poor and thus subject to bias. We observed major deficiencies such as lack of blinding or allocation concealment, inadequate randomization, high dropout rates, nonstandard outcome measurements, and inadequate reporting regarding the chromium product being investigated, the study methodology, the eligibility criteria, the statistical analyses, the baseline characteristics, and the outcomes. Our finding that for glucose outcomes, poor-quality studies were significantly more likely to yield favorable net effects than good- or fair-quality studies suggests that much of the apparent effects found may be largely due to biases related to poor methodology and reporting.

Similarly, there was a trend in at least one set of studies—those evaluating fasting glucose in participants with diabetes—that industry-sponsored studies may have been more likely to find a net benefit of chromium supplementation. In addition, the possibility of either conscious or unconscious biases, including publication bias where “negative” studies were withheld, must be considered. However, conclusions regarding funding source bias may be spurious, given the

relatively few studies available for analysis. Due to lack of an adequate measure of chromium nutrature and few such analyses, we were unable to address whether relatively chromium-depleted people would be more likely to benefit from supplementation.

Our meta-analysis is limited by the overall poor quality and heterogeneity of available studies. While we were able to explain some of the heterogeneity as being related to chromium dose, study quality, or funding source, there remained large differences in results across studies, even after accounting for different chromium formulations.

In conclusion, we found that chromium supplementation in patients with type 2 diabetes may have a modest beneficial effect on glycemia and dyslipidemia. In contrast, there was no beneficial effect of chromium supplementation on glycemia or lipids in those without diabetes. The large heterogeneity across these studies and the overall poor quality limit the strength of our conclusions. By elucidating the body of evidence on chromium supplementation, our meta-analysis highlights the questions that remain and the issues that need to be addressed in future randomized trials of chromium on glucose and lipid metabolism.

**Acknowledgments**— This review was funded by the Agency for Healthcare Research and Quality (contract no. 290-02-0023). A.G.P. received funding from the National Institutes of Health (K23-DK61506).

## References

1. Cefalu WT, Hu FB: Role of chromium in human health and in diabetes. *Diabetes Care* 27:2741–2751, 2004
2. Jain SK, Lim G: Chromium chloride inhibits TNF $\alpha$  and IL-6 secretion in isolated human blood mononuclear cells exposed to high glucose. *Horm Metab Res* 38:60–62, 2006
3. Jain SK, Patel P, Rogier K, Jain SK: Trivalent chromium inhibits protein glycosylation and lipid peroxidation in high glucose-treated erythrocytes. *Antioxid Redox Signal* 8:238–241, 2006
4. Schwarz K, Mertz W: Chromium(III) and the glucose tolerance factor. *Arch Biochem Biophys* 85:292–295, 1959
5. Evans GW, Pouchnik DJ: Composition and biological activity of chromium-pyridine carboxylate complexes. *J Inorg Biochem* 49:177–187, 1993
6. Jeejeebhoy KN, Chu RC, Marliss EB, Greenberg GR, Bruce-Robertson A: Chromium deficiency, glucose intolerance,

- and neuropathy reversed by chromium supplementation, in a patient receiving long-term total parenteral nutrition. *Am J Clin Nutr* 30:531–538, 1977
7. Brown RO, Forloines-Lynn S, Cross RE, Heizer WD: Chromium deficiency after long-term total parenteral nutrition. *Dig Dis Sci* 31:661–664, 1986
  8. Freund H, Atamian S, Fischer JE: Chromium deficiency during total parenteral nutrition. *JAMA* 241:496–498, 1979
  9. Office of Dietary Supplements: Dietary supplement fact sheet: chromium [article online], 2006. Available from <http://ods.od.nih.gov/factsheets/chromium.asp#en55>. Accessed 6 October 2006
  10. Balk E, Tatsioni A, Chung M, Pittas A, Lichtenstein A, Lau J: Evidence supporting proposed food-related health claims for chromium picolinate supplementation: September 21, 2004 [article online]. Available from <http://www.fda.gov/ohrms/dockets/dockets/04q0144/04q-0144-rpt0001-01.pdf>. Accessed 6 October 2006
  11. Docket 2004Q-0144: qualified health claim (QHC): chromium picolinate and diabetes: December 1, 2004 [article online]. Available from <http://www.fda.gov/ohrms/dockets/dockets/04q0144/04q0144.htm>. Accessed 6 October 2006
  12. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, Kitzmiller J, Knowler WC, Lebovitz H, Lernmark A, Nathan D, Palmer J, Rizza R, Saudek C, Shaw J, Stefes M, Stern M, Tuomilehto J, Zimmet P, Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Follow-up report on the diagnosis of diabetes mellitus. *Diabetes Care* 26:3160–3167, 2003
  13. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation: 1999. Geneva, World Health Org. Department of Noncommunicable Disease Surveillance, 1999
  14. Simonoff M: Chromium deficiency and cardiovascular risk. *Cardiovasc Res* 18: 591–596, 1984
  15. DerSimonian R, Laird N: Meta-analysis in clinical trials. *Control Clin Trials* 7:177–188, 1986
  16. Goldstein DE, Little RR, Lorenz RA, Malone JI, Nathan D, Peterson CM, Sacks DB: Tests of glycemia in diabetes. *Diabetes Care* 27:1761–1773, 2004
  17. National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification: Kidney Disease Outcome Quality Initiative. *Am J Kidney Dis* 39 (Suppl. 1):S223–S231, 2002
  18. Racek J, Trefil L, Rajdl D, Mudrova V, Hunter D, Senft V: Influence of chromium-enriched yeast on blood glucose and insulin variables, blood lipids, and markers of oxidative stress in subjects with type



- 2 diabetes mellitus. *Biol Trace Elem Res* 109:215–230, 2006
19. Grant AP, McMullen JK: The effect of brewers yeast containing glucose tolerance factor on the response to treatment in type 2 diabetics: a short controlled study. *Ulster Med J* 51:110–114, 1982
  20. Uusitupa MI, Mykkanen L, Siitonen O, Laakso M, Sarlund H, Kolehmainen P, Rasanen T, Kumpulainen J, Pyorala K: Chromium supplementation in impaired glucose tolerance of elderly: effects on blood glucose, plasma insulin, C-peptide and lipid levels. *Br J Nutr* 68:209–216, 1992
  21. Bahijiri SM, Mira SA, Mufti AM, Ajabnoor MA: The effects of inorganic chromium and brewer's yeast supplementation on glucose tolerance, serum lipids and drug dosage in individuals with type 2 diabetes. *Saudi Med J* 21:831–837, 2000
  22. Rabinowitz MB, Gonick HC, Levin SR, Davidson MB: Effects of chromium and yeast supplements on carbohydrate and lipid metabolism in diabetic men. *Diabetes Care* 6:319–327, 1983
  23. Offenbacher EG, Pi-Sunyer FX: Beneficial effect of chromium-rich yeast on glucose tolerance and blood lipids in elderly subjects. *Diabetes* 29:919–925, 1980
  24. Wang MM, Fox EA, Stoecker BJ, Menendez CE, Chan SB: Serum cholesterol of adults supplemented with brewer's yeast or chromium chloride. *Nutr Res* 9:989–998, 1989
  25. Li YC, Shin SJ, Chen JC: Effects of brewer's yeast and torula yeast on glucose tolerance, serum lipids and chromium contents in adult human beings. *J Chin Nutr Soc* 17:147–155, 1992
  26. Li YC: Effects of brewer's yeast on glucose tolerance and serum lipids in Chinese adults. *Biol Trace Elem Res* 41:341–347, 1994
  27. Offenbacher EG, Rinko CJ, PiSunyer FX: The effects of inorganic chromium and brewer's yeast on glucose tolerance, plasma lipids, and plasma chromium in elderly subjects. *Am J Clin Nutr* 42:454–461, 1985
  28. Uusitupa MI, Kumpulainen JT, Voutilainen E, Hersio K, Sarlund H, Pyorala KP, Koivisto PE, Lehto JT: Effect of inorganic chromium supplementation on glucose tolerance, insulin response, and serum lipids in noninsulin-dependent diabetics. *Am J Clin Nutr* 38:404–410, 1983
  29. Mossop RT: Effects of chromium III on fasting blood glucose, cholesterol and cholesterol HDL levels in diabetics. *Cent Afr J Med* 29:80–82, 1983
  30. Abraham AS, Brooks BA, Eylath U: The effects of chromium supplementation on serum glucose and lipids in patients with and without non-insulin-dependent diabetes. *Metabolism* 41:768–771, 1992
  31. Sherman L, Glennon JA, Brech WJ, Klomberg GH, Gordon ES: Failure of trivalent chromium to improve hyperglycemia in diabetes mellitus. *Metabolism* 17:439–442, 1968
  32. Anderson RA, Polansky MM, Bryden NA, Roginski EE, Mertz W, Glinemann W: Chromium supplementation of human subjects: effects on glucose, insulin, and lipid variables. *Metabolism* 32:894–899, 1983
  33. Anderson RA, Polansky MM, Bryden NA, Canary JJ: Supplemental-chromium effects on glucose, insulin, glucagon, and urinary chromium losses in subjects consuming controlled low-chromium diets. *Am J Clin Nutr* 54:909–916, 1991
  34. Martinez OB, MacDonald AC, Gibson RS, Bourn D: Dietary chromium and effect of chromium supplementation on glucose tolerance of elderly Canadian women. *Nutr Res* 5:609–620, 1985
  35. Hermann J, Chung H, Arquitt A, Goad C, Burns M, Chan B: Effects of chromium or copper supplementation on plasma lipids, plasma glucose and serum insulin in adults over age fifty. *J Nutr Elder* 18:27–45, 1998
  36. Bahijiri SM: Effect of chromium supplementation on glucose tolerance and lipid profile. *Saudi Med J* 21:45–50, 2000
  37. Riales R, Albrink MJ: Effect of chromium chloride supplementation on glucose tolerance and serum lipids including high-density lipoprotein of adult men. *Am J Clin Nutr* 34:2670–2678, 1981
  38. Hermann J, Arquitt A, Stoecker B: Effects of chromium supplementation on plasma lipids, apolipoproteins, and glucose in elderly subjects. *Nutr Res* 14:671–674, 1994
  39. Grant KE, Chandler RM, Castle AL, Ivy JL: Chromium and exercise training: effect on obese women. *Med Sci Sports Exerc* 29:992–998, 1997
  40. Crawford V, Scheckenbach R, Preuss HG: Effects of niacin-bound chromium supplementation on body composition in overweight African-American women. *Diabetes Obes Metab* 1:331–337, 1999
  41. Lefavi RG, Wilson GD, Keith RE, Anderson RA, Blessing DL, Hames CG, McMullan JL: Lipid-lowering effect of dietary chromium (iii)-nicotinic acid complex in male athletes. *Nutr Res* 13:239–249, 1993
  42. Wilson BE, Gondy A: Effects of chromium supplementation on fasting insulin levels and lipid parameters in healthy, non-obese young subjects. *Diabetes Res Clin Pract* 28:179–184, 1995
  43. Urberg M, Zemel MB: Evidence for synergism between chromium and nicotinic acid in the control of glucose tolerance in elderly humans. *Metabolism* 36:896–899, 1987
  44. Anderson RA, Cheng N, Bryden NA, Polansky MM, Cheng N, Chi J, Feng J: Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. *Diabetes* 46:1786–1791, 1997
  45. Kleefstra N, Houweling ST, Jansman FG, Groenier KH, Gans RO, Meyboom-de Jong B, Bakker SJ, Bilo HJ: Chromium treatment has no effect in patients with poorly controlled, insulin-treated type 2 diabetes in an obese Western population: a randomized, double-blind, placebo-controlled trial. *Diabetes Care* 29:521–525, 2006
  46. Martin J, Wang ZQ, Zhang XH, Wachtel D, Volaufova J, Matthews DE, Cefalu WT: Chromium picolinate supplementation attenuates body weight gain and increases insulin sensitivity in subjects with type 2 diabetes. *Diabetes Care* 29:1826–1832, 2006
  47. Vrtovec M, Vrtovec B, Briski A, Kocijancic A, Anderson RA, Radovancevic B: Chromium supplementation shortens QTc interval duration in patients with type 2 diabetes mellitus. *Am Heart J* 149:632–636, 2005
  48. Ghosh D, Bhattacharya B, Mukherjee B, Manna B, Sinha M, Chowdhury J, Chowdhury S: Role of chromium supplementation in Indians with type 2 diabetes mellitus. *J Nutr Biochem* 13:690–697, 2002
  49. Evans GW: The effect of chromium picolinate on insulin controlled parameters in humans. *Int J Biosoc Med Res* 11:163–180, 1989
  50. Lee NA, Reasner CA: Beneficial effect of chromium supplementation on serum triglyceride levels in NIDDM. *Diabetes Care* 17:1449–1452, 1994
  51. Cefalu WT, Bell-Farrow AD, Stegner J, Wang ZQ, King T, Morgan T, Terry JG: Effect of chromium picolinate on insulin sensitivity in vivo. *J Trace Elem Exp Med* 12:71–83, 1999
  52. Rabinovitz H, Friedensohn A, Leibovitz A, Gabay G, Rocas C, Habet B: Effect of chromium supplementation on blood glucose and lipid levels in type 2 diabetes mellitus elderly patients. *Int J Vitam Nutr Res* 74:178–182, 2004
  53. Volpe SL, Huang HW, Larpadisorn K, Lesser II: Effect of chromium supplementation and exercise on body composition, resting metabolic rate and selected biochemical parameters in moderately obese women following an exercise program. *J Am Coll Nutr* 20:293–306, 2001
  54. Gunton JE, Cheung NW, Hitchman R, Hams G, O'Sullivan C, Foster-Powell K, McElduff A: Chromium supplementation does not improve glucose tolerance, insulin sensitivity, or lipid profile: a randomized, placebo-controlled, double-blind trial of supplementation in subjects with impaired glucose tolerance. *Diabetes Care* 28:712–713, 2005
  55. Joseph LJ, Farrell PA, Davey SL, Evans

- WJ, Campbell WW: Effect of resistance training with or without chromium picolinate supplementation on glucose metabolism in older men and women. *Metabolism* 48:546–553, 1999
56. Lucidi RS, Thyer AC, Easton CA, Holden AE, Schenken RS, Brzyski RG: Effect of chromium supplementation on insulin resistance and ovarian and menstrual cyclicality in women with polycystic ovary syndrome. *Fertil Steril* 84:1755–1757, 2005
57. Amato P, Morales AJ, Yen SS: Effects of chromium picolinate supplementation on insulin sensitivity, serum lipids, and body composition in healthy, nonobese, older men and women. *J Gerontol A Biol Sci Med Sci* 55:M260–M263, 2000
58. Pei D, Hsieh CH, Hung YJ, Li JC, Lee CH, Kuo SW: The influence of chromium chloride-containing milk to glycemic control of patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial. *Metabolism* 55:923–927, 2006
59. U.S. Food and Drug Administration: Qualified health claims: letter of enforcement discretion: chromium picolinate and insulin resistance: (docket no. 2004Q-0144) [article online], 2005. Available from <http://www.cfsan.fda.gov/~dms/qrccr.html>. Accessed 6 October 2006